Clinical Trials

Clinical Trial Detail

Return to search results.

Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children

Complete title: Enhancing Connections Telephone Program: A Cancer Education Program for Parents

Research Study Number       9095
Principal Investigator       Frances Lewis
Phase       Pilot

Look up trial at NIH

Research Study Description

This pilot clinical trial studies the feasibility of a telephone-based educational intervention in improving communication between patients with stage 0-III cancer and their children. An educational program delivered by telephone may help parents talk with their school-age child about their cancer.

Eligibility Criteria (must meet the following to participate in this study)

Ages Eligible for Study: 18 Years and older

Genders Eligible for Study: Both

- Parents will be eligible if they have an initial diagnosis of non-metastatic cancer of any type (stage 0-3), including melanoma, colorectal, cervical, leukemia, lymphoma or breast cancer within the past 7 months

- Read and write English among their languages of choice

- Have ready access to a telephone

- Have a child 5-12 years old living at home who has been told their parent's cancer diagnosis

- The child is living at home and does not have learning challenges

- No prior malignancy is allowed except for adequately treated basal (or squamous cell) skin cancer

Other eligibility criteria may apply.

Research Study Number       9095
Contact       Frances Lewis
Telephone       206/685-0808

Hematologic Malignancies; Solid Tumors

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

Subscribe to an RSS feed of all trials